nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—muscle cancer	0.33	1	CiPCiCtD
Pemetrexed—Methotrexate—muscle cancer	0.217	1	CrCtD
Pemetrexed—lung cancer—muscle cancer	0.159	1	CtDrD
Pemetrexed—ATIC—Methotrexate—muscle cancer	0.0442	0.377	CbGbCtD
Pemetrexed—SLC46A1—Methotrexate—muscle cancer	0.0351	0.299	CbGbCtD
Pemetrexed—Pralatrexate—Methotrexate—muscle cancer	0.0287	0.2	CrCrCtD
Pemetrexed—Raltitrexed—Methotrexate—muscle cancer	0.0287	0.2	CrCrCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—muscle cancer	0.0287	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—muscle cancer	0.0287	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—muscle cancer	0.0287	0.2	CrCrCtD
Pemetrexed—DHFR—Methotrexate—muscle cancer	0.0225	0.191	CbGbCtD
Pemetrexed—TYMS—Methotrexate—muscle cancer	0.0156	0.133	CbGbCtD
Pemetrexed—ATIC—pes—muscle cancer	0.00309	0.21	CbGeAlD
Pemetrexed—ATIC—hindlimb—muscle cancer	0.00141	0.0958	CbGeAlD
Pemetrexed—ATIC—appendage—muscle cancer	0.00121	0.0821	CbGeAlD
Pemetrexed—GART—renal system—muscle cancer	0.000447	0.0304	CbGeAlD
Pemetrexed—ATIC—embryo—muscle cancer	0.000401	0.0273	CbGeAlD
Pemetrexed—GART—cardiac atrium—muscle cancer	0.0004	0.0272	CbGeAlD
Pemetrexed—GART—tendon—muscle cancer	0.000349	0.0237	CbGeAlD
Pemetrexed—GART—bone marrow—muscle cancer	0.000338	0.023	CbGeAlD
Pemetrexed—GART—vagina—muscle cancer	0.000323	0.022	CbGeAlD
Pemetrexed—ATIC—smooth muscle tissue—muscle cancer	0.000315	0.0214	CbGeAlD
Pemetrexed—ATIC—renal system—muscle cancer	0.000303	0.0206	CbGeAlD
Pemetrexed—GART—head—muscle cancer	0.000299	0.0203	CbGeAlD
Pemetrexed—GART—testis—muscle cancer	0.000289	0.0197	CbGeAlD
Pemetrexed—SLC46A1—tendon—muscle cancer	0.000283	0.0193	CbGeAlD
Pemetrexed—DHFR—embryo—muscle cancer	0.000269	0.0183	CbGeAlD
Pemetrexed—SLC46A1—head—muscle cancer	0.000243	0.0165	CbGeAlD
Pemetrexed—SLC46A1—testis—muscle cancer	0.000234	0.016	CbGeAlD
Pemetrexed—DCK—embryo—muscle cancer	0.000233	0.0158	CbGeAlD
Pemetrexed—TYMS—smooth muscle tissue—muscle cancer	0.000214	0.0145	CbGeAlD
Pemetrexed—DHFR—renal system—muscle cancer	0.000204	0.0139	CbGeAlD
Pemetrexed—ATIC—head—muscle cancer	0.000203	0.0138	CbGeAlD
Pemetrexed—ATIC—testis—muscle cancer	0.000196	0.0133	CbGeAlD
Pemetrexed—SLC29A1—renal system—muscle cancer	0.000184	0.0126	CbGeAlD
Pemetrexed—DHFR—cardiac atrium—muscle cancer	0.000182	0.0124	CbGeAlD
Pemetrexed—TYMS—Vinorelbine—Vincristine—muscle cancer	0.000169	0.301	CbGdCrCtD
Pemetrexed—TYMS—Podofilox—Etoposide—muscle cancer	0.000169	0.3	CbGdCrCtD
Pemetrexed—SLC29A1—cardiac atrium—muscle cancer	0.000165	0.0112	CbGeAlD
Pemetrexed—TYMS—tendon—muscle cancer	0.000161	0.0109	CbGeAlD
Pemetrexed—DHFR—tendon—muscle cancer	0.000159	0.0108	CbGeAlD
Pemetrexed—DCK—cardiac atrium—muscle cancer	0.000158	0.0107	CbGeAlD
Pemetrexed—TYMS—bone marrow—muscle cancer	0.000156	0.0106	CbGeAlD
Pemetrexed—DHFR—bone marrow—muscle cancer	0.000154	0.0105	CbGeAlD
Pemetrexed—TYMS—vagina—muscle cancer	0.000149	0.0101	CbGeAlD
Pemetrexed—DHFR—vagina—muscle cancer	0.000148	0.01	CbGeAlD
Pemetrexed—SLC29A1—tendon—muscle cancer	0.000144	0.0098	CbGeAlD
Pemetrexed—SLC29A1—bone marrow—muscle cancer	0.000139	0.00949	CbGeAlD
Pemetrexed—TYMS—head—muscle cancer	0.000138	0.00937	CbGeAlD
Pemetrexed—DCK—tendon—muscle cancer	0.000138	0.00936	CbGeAlD
Pemetrexed—DHFR—head—muscle cancer	0.000136	0.00928	CbGeAlD
Pemetrexed—SLC29A1—vagina—muscle cancer	0.000134	0.0091	CbGeAlD
Pemetrexed—DCK—bone marrow—muscle cancer	0.000133	0.00907	CbGeAlD
Pemetrexed—TYMS—testis—muscle cancer	0.000133	0.00905	CbGeAlD
Pemetrexed—DHFR—testis—muscle cancer	0.000132	0.00896	CbGeAlD
Pemetrexed—DCK—vagina—muscle cancer	0.000128	0.00869	CbGeAlD
Pemetrexed—SLC29A1—head—muscle cancer	0.000123	0.0084	CbGeAlD
Pemetrexed—SLC29A1—testis—muscle cancer	0.000119	0.00812	CbGeAlD
Pemetrexed—DCK—head—muscle cancer	0.000118	0.00803	CbGeAlD
Pemetrexed—TYMS—Vinblastine—Vincristine—muscle cancer	0.000116	0.207	CbGdCrCtD
Pemetrexed—DCK—testis—muscle cancer	0.000114	0.00775	CbGeAlD
Pemetrexed—DCK—Epirubicin—Doxorubicin—muscle cancer	0.000108	0.193	CbGdCrCtD
Pemetrexed—Myocardial infarction—Vincristine—muscle cancer	6.75e-05	0.0037	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Vincristine—muscle cancer	6.75e-05	0.0037	CcSEcCtD
Pemetrexed—Stomatitis—Vincristine—muscle cancer	6.71e-05	0.00368	CcSEcCtD
Pemetrexed—Erythema multiforme—Dactinomycin—muscle cancer	6.54e-05	0.00359	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Etoposide—muscle cancer	6.52e-05	0.00357	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Etoposide—muscle cancer	6.39e-05	0.0035	CcSEcCtD
Pemetrexed—Dysphagia—Etoposide—muscle cancer	6.26e-05	0.00343	CcSEcCtD
Pemetrexed—Alopecia—Dactinomycin—muscle cancer	6.12e-05	0.00335	CcSEcCtD
Pemetrexed—Urinary tract disorder—Vincristine—muscle cancer	6.11e-05	0.00335	CcSEcCtD
Pemetrexed—Respiratory failure—Methotrexate—muscle cancer	6.08e-05	0.00333	CcSEcCtD
Pemetrexed—Urethral disorder—Vincristine—muscle cancer	6.06e-05	0.00332	CcSEcCtD
Pemetrexed—Neoplasm malignant—Doxorubicin—muscle cancer	6.06e-05	0.00332	CcSEcCtD
Pemetrexed—Erythema—Dactinomycin—muscle cancer	6.02e-05	0.0033	CcSEcCtD
Pemetrexed—Pulmonary embolism—Methotrexate—muscle cancer	5.97e-05	0.00327	CcSEcCtD
Pemetrexed—Pancytopenia—Etoposide—muscle cancer	5.94e-05	0.00326	CcSEcCtD
Pemetrexed—Neutropenia—Etoposide—muscle cancer	5.85e-05	0.00321	CcSEcCtD
Pemetrexed—Rectal haemorrhage—Doxorubicin—muscle cancer	5.73e-05	0.00314	CcSEcCtD
Pemetrexed—Skin exfoliation—Methotrexate—muscle cancer	5.7e-05	0.00313	CcSEcCtD
Pemetrexed—Lacrimation increased—Doxorubicin—muscle cancer	5.61e-05	0.00308	CcSEcCtD
Pemetrexed—Infestation NOS—Etoposide—muscle cancer	5.58e-05	0.00306	CcSEcCtD
Pemetrexed—Infestation—Etoposide—muscle cancer	5.58e-05	0.00306	CcSEcCtD
Pemetrexed—Anaemia—Dactinomycin—muscle cancer	5.57e-05	0.00305	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Etoposide—muscle cancer	5.53e-05	0.00303	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Etoposide—muscle cancer	5.5e-05	0.00301	CcSEcCtD
Pemetrexed—Renal failure—Etoposide—muscle cancer	5.48e-05	0.00301	CcSEcCtD
Pemetrexed—Myocardial infarction—Etoposide—muscle cancer	5.47e-05	0.003	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Etoposide—muscle cancer	5.47e-05	0.003	CcSEcCtD
Pemetrexed—Alopecia—Vincristine—muscle cancer	5.46e-05	0.00299	CcSEcCtD
Pemetrexed—Stomatitis—Etoposide—muscle cancer	5.44e-05	0.00298	CcSEcCtD
Pemetrexed—Creatinine increased—Doxorubicin—muscle cancer	5.43e-05	0.00298	CcSEcCtD
Pemetrexed—Leukopenia—Dactinomycin—muscle cancer	5.39e-05	0.00296	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Etoposide—muscle cancer	5.28e-05	0.00289	CcSEcCtD
Pemetrexed—Agranulocytosis—Etoposide—muscle cancer	5.21e-05	0.00285	CcSEcCtD
Pemetrexed—Sepsis—Methotrexate—muscle cancer	5.18e-05	0.00284	CcSEcCtD
Pemetrexed—Pulmonary embolism—Doxorubicin—muscle cancer	5.17e-05	0.00284	CcSEcCtD
Pemetrexed—Ventricular tachycardia—Doxorubicin—muscle cancer	5.17e-05	0.00284	CcSEcCtD
Pemetrexed—Myalgia—Dactinomycin—muscle cancer	5.13e-05	0.00281	CcSEcCtD
Pemetrexed—Anaemia—Vincristine—muscle cancer	4.97e-05	0.00273	CcSEcCtD
Pemetrexed—Colitis—Doxorubicin—muscle cancer	4.97e-05	0.00272	CcSEcCtD
Pemetrexed—Urinary tract disorder—Etoposide—muscle cancer	4.95e-05	0.00271	CcSEcCtD
Pemetrexed—Skin exfoliation—Doxorubicin—muscle cancer	4.94e-05	0.00271	CcSEcCtD
Pemetrexed—Oedema—Dactinomycin—muscle cancer	4.92e-05	0.00269	CcSEcCtD
Pemetrexed—Urethral disorder—Etoposide—muscle cancer	4.91e-05	0.00269	CcSEcCtD
Pemetrexed—Infection—Dactinomycin—muscle cancer	4.88e-05	0.00268	CcSEcCtD
Pemetrexed—Neuropathy—Doxorubicin—muscle cancer	4.86e-05	0.00266	CcSEcCtD
Pemetrexed—Leukopenia—Vincristine—muscle cancer	4.82e-05	0.00264	CcSEcCtD
Pemetrexed—Thrombocytopenia—Dactinomycin—muscle cancer	4.81e-05	0.00264	CcSEcCtD
Pemetrexed—Erythema multiforme—Etoposide—muscle cancer	4.74e-05	0.0026	CcSEcCtD
Pemetrexed—Oesophagitis—Doxorubicin—muscle cancer	4.73e-05	0.00259	CcSEcCtD
Pemetrexed—Renal failure acute—Methotrexate—muscle cancer	4.7e-05	0.00257	CcSEcCtD
Pemetrexed—Anorexia—Dactinomycin—muscle cancer	4.69e-05	0.00257	CcSEcCtD
Pemetrexed—Eye disorder—Etoposide—muscle cancer	4.68e-05	0.00257	CcSEcCtD
Pemetrexed—Hypertension—Vincristine—muscle cancer	4.65e-05	0.00255	CcSEcCtD
Pemetrexed—Myalgia—Vincristine—muscle cancer	4.58e-05	0.00251	CcSEcCtD
Pemetrexed—Sepsis—Doxorubicin—muscle cancer	4.49e-05	0.00246	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Dactinomycin—muscle cancer	4.48e-05	0.00245	CcSEcCtD
Pemetrexed—Alopecia—Etoposide—muscle cancer	4.43e-05	0.00243	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Methotrexate—muscle cancer	4.43e-05	0.00243	CcSEcCtD
Pemetrexed—Anaphylactic shock—Vincristine—muscle cancer	4.39e-05	0.00241	CcSEcCtD
Pemetrexed—Oedema—Vincristine—muscle cancer	4.39e-05	0.00241	CcSEcCtD
Pemetrexed—Infection—Vincristine—muscle cancer	4.36e-05	0.00239	CcSEcCtD
Pemetrexed—Nervous system disorder—Vincristine—muscle cancer	4.31e-05	0.00236	CcSEcCtD
Pemetrexed—Thrombocytopenia—Vincristine—muscle cancer	4.3e-05	0.00236	CcSEcCtD
Pemetrexed—Decreased appetite—Dactinomycin—muscle cancer	4.27e-05	0.00234	CcSEcCtD
Pemetrexed—Dysgeusia—Etoposide—muscle cancer	4.27e-05	0.00234	CcSEcCtD
Pemetrexed—Fatigue—Dactinomycin—muscle cancer	4.24e-05	0.00232	CcSEcCtD
Pemetrexed—Pain—Dactinomycin—muscle cancer	4.2e-05	0.0023	CcSEcCtD
Pemetrexed—Anorexia—Vincristine—muscle cancer	4.19e-05	0.00229	CcSEcCtD
Pemetrexed—Mood swings—Methotrexate—muscle cancer	4.11e-05	0.00225	CcSEcCtD
Pemetrexed—Renal failure acute—Doxorubicin—muscle cancer	4.07e-05	0.00223	CcSEcCtD
Pemetrexed—Anaemia—Etoposide—muscle cancer	4.03e-05	0.00221	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Dactinomycin—muscle cancer	4.02e-05	0.0022	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Vincristine—muscle cancer	4e-05	0.00219	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Methotrexate—muscle cancer	3.9e-05	0.00214	CcSEcCtD
Pemetrexed—Leukopenia—Etoposide—muscle cancer	3.9e-05	0.00214	CcSEcCtD
Pemetrexed—Abdominal pain—Dactinomycin—muscle cancer	3.89e-05	0.00213	CcSEcCtD
Pemetrexed—Body temperature increased—Dactinomycin—muscle cancer	3.89e-05	0.00213	CcSEcCtD
Pemetrexed—Loss of consciousness—Etoposide—muscle cancer	3.83e-05	0.0021	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Doxorubicin—muscle cancer	3.83e-05	0.0021	CcSEcCtD
Pemetrexed—Decreased appetite—Vincristine—muscle cancer	3.82e-05	0.00209	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Vincristine—muscle cancer	3.79e-05	0.00208	CcSEcCtD
Pemetrexed—Fatigue—Vincristine—muscle cancer	3.79e-05	0.00208	CcSEcCtD
Pemetrexed—Hypertension—Etoposide—muscle cancer	3.76e-05	0.00206	CcSEcCtD
Pemetrexed—Pain—Vincristine—muscle cancer	3.76e-05	0.00206	CcSEcCtD
Pemetrexed—Constipation—Vincristine—muscle cancer	3.76e-05	0.00206	CcSEcCtD
Pemetrexed—Chest pain—Etoposide—muscle cancer	3.71e-05	0.00203	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	3.69e-05	0.00202	CcSEcCtD
Pemetrexed—Pancreatitis—Methotrexate—muscle cancer	3.67e-05	0.00201	CcSEcCtD
Pemetrexed—Hypersensitivity—Dactinomycin—muscle cancer	3.62e-05	0.00199	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Vincristine—muscle cancer	3.59e-05	0.00197	CcSEcCtD
Pemetrexed—Pancytopenia—Methotrexate—muscle cancer	3.56e-05	0.00195	CcSEcCtD
Pemetrexed—Anaphylactic shock—Etoposide—muscle cancer	3.56e-05	0.00195	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—muscle cancer	3.56e-05	0.00195	CcSEcCtD
Pemetrexed—Infection—Etoposide—muscle cancer	3.54e-05	0.00194	CcSEcCtD
Pemetrexed—Asthenia—Dactinomycin—muscle cancer	3.53e-05	0.00193	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—muscle cancer	3.52e-05	0.00193	CcSEcCtD
Pemetrexed—Neutropenia—Methotrexate—muscle cancer	3.5e-05	0.00192	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—muscle cancer	3.49e-05	0.00191	CcSEcCtD
Pemetrexed—Thrombocytopenia—Etoposide—muscle cancer	3.48e-05	0.00191	CcSEcCtD
Pemetrexed—Abdominal pain—Vincristine—muscle cancer	3.47e-05	0.0019	CcSEcCtD
Pemetrexed—Body temperature increased—Vincristine—muscle cancer	3.47e-05	0.0019	CcSEcCtD
Pemetrexed—Skin disorder—Etoposide—muscle cancer	3.46e-05	0.00189	CcSEcCtD
Pemetrexed—Anorexia—Etoposide—muscle cancer	3.39e-05	0.00186	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	3.38e-05	0.00185	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	3.38e-05	0.00185	CcSEcCtD
Pemetrexed—Diarrhoea—Dactinomycin—muscle cancer	3.36e-05	0.00184	CcSEcCtD
Pemetrexed—Infestation NOS—Methotrexate—muscle cancer	3.34e-05	0.00183	CcSEcCtD
Pemetrexed—Infestation—Methotrexate—muscle cancer	3.34e-05	0.00183	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Methotrexate—muscle cancer	3.31e-05	0.00182	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—muscle cancer	3.31e-05	0.00182	CcSEcCtD
Pemetrexed—Renal failure—Methotrexate—muscle cancer	3.29e-05	0.0018	CcSEcCtD
Pemetrexed—Stomatitis—Methotrexate—muscle cancer	3.26e-05	0.00179	CcSEcCtD
Pemetrexed—Conjunctivitis—Methotrexate—muscle cancer	3.25e-05	0.00178	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—muscle cancer	3.25e-05	0.00178	CcSEcCtD
Pemetrexed—Hypersensitivity—Vincristine—muscle cancer	3.24e-05	0.00177	CcSEcCtD
Pemetrexed—Pancreatitis—Doxorubicin—muscle cancer	3.18e-05	0.00174	CcSEcCtD
Pemetrexed—Dyspnoea—Etoposide—muscle cancer	3.17e-05	0.00174	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—muscle cancer	3.16e-05	0.00173	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Methotrexate—muscle cancer	3.16e-05	0.00173	CcSEcCtD
Pemetrexed—Asthenia—Vincristine—muscle cancer	3.15e-05	0.00173	CcSEcCtD
Pemetrexed—Vomiting—Dactinomycin—muscle cancer	3.13e-05	0.00171	CcSEcCtD
Pemetrexed—Agranulocytosis—Methotrexate—muscle cancer	3.12e-05	0.00171	CcSEcCtD
Pemetrexed—Rash—Dactinomycin—muscle cancer	3.1e-05	0.0017	CcSEcCtD
Pemetrexed—Decreased appetite—Etoposide—muscle cancer	3.09e-05	0.0017	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—muscle cancer	3.08e-05	0.00169	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Etoposide—muscle cancer	3.07e-05	0.00168	CcSEcCtD
Pemetrexed—Fatigue—Etoposide—muscle cancer	3.07e-05	0.00168	CcSEcCtD
Pemetrexed—Pain—Etoposide—muscle cancer	3.04e-05	0.00167	CcSEcCtD
Pemetrexed—Constipation—Etoposide—muscle cancer	3.04e-05	0.00167	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—muscle cancer	3.03e-05	0.00166	CcSEcCtD
Pemetrexed—Diarrhoea—Vincristine—muscle cancer	3.01e-05	0.00165	CcSEcCtD
Pemetrexed—Hepatitis—Methotrexate—muscle cancer	3e-05	0.00164	CcSEcCtD
Pemetrexed—Pharyngitis—Methotrexate—muscle cancer	2.98e-05	0.00163	CcSEcCtD
Pemetrexed—Urinary tract disorder—Methotrexate—muscle cancer	2.96e-05	0.00162	CcSEcCtD
Pemetrexed—Urethral disorder—Methotrexate—muscle cancer	2.94e-05	0.00161	CcSEcCtD
Pemetrexed—Nausea—Dactinomycin—muscle cancer	2.92e-05	0.0016	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Etoposide—muscle cancer	2.91e-05	0.00159	CcSEcCtD
Pemetrexed—Dizziness—Vincristine—muscle cancer	2.9e-05	0.00159	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—muscle cancer	2.89e-05	0.00159	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—muscle cancer	2.89e-05	0.00159	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	2.87e-05	0.00157	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—muscle cancer	2.84e-05	0.00156	CcSEcCtD
Pemetrexed—Erythema multiforme—Methotrexate—muscle cancer	2.84e-05	0.00155	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—muscle cancer	2.84e-05	0.00155	CcSEcCtD
Pemetrexed—Urticaria—Etoposide—muscle cancer	2.83e-05	0.00155	CcSEcCtD
Pemetrexed—Stomatitis—Doxorubicin—muscle cancer	2.82e-05	0.00155	CcSEcCtD
Pemetrexed—Body temperature increased—Etoposide—muscle cancer	2.81e-05	0.00154	CcSEcCtD
Pemetrexed—Abdominal pain—Etoposide—muscle cancer	2.81e-05	0.00154	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—muscle cancer	2.81e-05	0.00154	CcSEcCtD
Pemetrexed—Eye disorder—Methotrexate—muscle cancer	2.8e-05	0.00154	CcSEcCtD
Pemetrexed—Vomiting—Vincristine—muscle cancer	2.79e-05	0.00153	CcSEcCtD
Pemetrexed—Rash—Vincristine—muscle cancer	2.77e-05	0.00152	CcSEcCtD
Pemetrexed—Dermatitis—Vincristine—muscle cancer	2.77e-05	0.00152	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—muscle cancer	2.74e-05	0.0015	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—muscle cancer	2.7e-05	0.00148	CcSEcCtD
Pemetrexed—Alopecia—Methotrexate—muscle cancer	2.65e-05	0.00145	CcSEcCtD
Pemetrexed—Hypersensitivity—Etoposide—muscle cancer	2.62e-05	0.00144	CcSEcCtD
Pemetrexed—Malnutrition—Methotrexate—muscle cancer	2.61e-05	0.00143	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—muscle cancer	2.61e-05	0.00143	CcSEcCtD
Pemetrexed—Nausea—Vincristine—muscle cancer	2.61e-05	0.00143	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—muscle cancer	2.6e-05	0.00142	CcSEcCtD
Pemetrexed—Pharyngitis—Doxorubicin—muscle cancer	2.58e-05	0.00141	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—muscle cancer	2.57e-05	0.00141	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—muscle cancer	2.56e-05	0.0014	CcSEcCtD
Pemetrexed—Asthenia—Etoposide—muscle cancer	2.55e-05	0.0014	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—muscle cancer	2.55e-05	0.0014	CcSEcCtD
Pemetrexed—Pruritus—Etoposide—muscle cancer	2.52e-05	0.00138	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—muscle cancer	2.46e-05	0.00135	CcSEcCtD
Pemetrexed—Diarrhoea—Etoposide—muscle cancer	2.43e-05	0.00133	CcSEcCtD
Pemetrexed—Eye disorder—Doxorubicin—muscle cancer	2.43e-05	0.00133	CcSEcCtD
Pemetrexed—Anaemia—Methotrexate—muscle cancer	2.41e-05	0.00132	CcSEcCtD
Pemetrexed—Dizziness—Etoposide—muscle cancer	2.35e-05	0.00129	CcSEcCtD
Pemetrexed—Leukopenia—Methotrexate—muscle cancer	2.34e-05	0.00128	CcSEcCtD
Pemetrexed—Arrhythmia—Doxorubicin—muscle cancer	2.32e-05	0.00127	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—muscle cancer	2.3e-05	0.00126	CcSEcCtD
Pemetrexed—Vomiting—Etoposide—muscle cancer	2.26e-05	0.00124	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—muscle cancer	2.26e-05	0.00124	CcSEcCtD
Pemetrexed—Malnutrition—Doxorubicin—muscle cancer	2.26e-05	0.00124	CcSEcCtD
Pemetrexed—Rash—Etoposide—muscle cancer	2.24e-05	0.00123	CcSEcCtD
Pemetrexed—Dermatitis—Etoposide—muscle cancer	2.24e-05	0.00123	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—muscle cancer	2.22e-05	0.00122	CcSEcCtD
Pemetrexed—Chest pain—Methotrexate—muscle cancer	2.22e-05	0.00122	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—muscle cancer	2.22e-05	0.00122	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—muscle cancer	2.21e-05	0.00121	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	2.21e-05	0.00121	CcSEcCtD
Pemetrexed—Anaphylactic shock—Methotrexate—muscle cancer	2.13e-05	0.00117	CcSEcCtD
Pemetrexed—Infection—Methotrexate—muscle cancer	2.12e-05	0.00116	CcSEcCtD
Pemetrexed—Nausea—Etoposide—muscle cancer	2.11e-05	0.00116	CcSEcCtD
Pemetrexed—Nervous system disorder—Methotrexate—muscle cancer	2.09e-05	0.00115	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—muscle cancer	2.09e-05	0.00115	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—muscle cancer	2.09e-05	0.00114	CcSEcCtD
Pemetrexed—Skin disorder—Methotrexate—muscle cancer	2.07e-05	0.00113	CcSEcCtD
Pemetrexed—Anorexia—Methotrexate—muscle cancer	2.03e-05	0.00111	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—muscle cancer	2.03e-05	0.00111	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—muscle cancer	2.02e-05	0.00111	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—muscle cancer	1.99e-05	0.00109	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—muscle cancer	1.95e-05	0.00107	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—muscle cancer	1.94e-05	0.00106	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—muscle cancer	1.93e-05	0.00106	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—muscle cancer	1.93e-05	0.00106	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—muscle cancer	1.93e-05	0.00106	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	1.91e-05	0.00105	CcSEcCtD
Pemetrexed—Dyspnoea—Methotrexate—muscle cancer	1.9e-05	0.00104	CcSEcCtD
Pemetrexed—Dyspepsia—Methotrexate—muscle cancer	1.88e-05	0.00103	CcSEcCtD
Pemetrexed—Decreased appetite—Methotrexate—muscle cancer	1.85e-05	0.00102	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—muscle cancer	1.85e-05	0.00101	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—muscle cancer	1.85e-05	0.00101	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Methotrexate—muscle cancer	1.84e-05	0.00101	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—muscle cancer	1.84e-05	0.00101	CcSEcCtD
Pemetrexed—Infection—Doxorubicin—muscle cancer	1.83e-05	0.001	CcSEcCtD
Pemetrexed—Pain—Methotrexate—muscle cancer	1.82e-05	0.000999	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—muscle cancer	1.82e-05	0.000995	CcSEcCtD
Pemetrexed—Nervous system disorder—Doxorubicin—muscle cancer	1.81e-05	0.000992	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—muscle cancer	1.81e-05	0.00099	CcSEcCtD
Pemetrexed—Skin disorder—Doxorubicin—muscle cancer	1.79e-05	0.000982	CcSEcCtD
Pemetrexed—Anorexia—Doxorubicin—muscle cancer	1.76e-05	0.000964	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—muscle cancer	1.74e-05	0.000955	CcSEcCtD
Pemetrexed—Urticaria—Methotrexate—muscle cancer	1.69e-05	0.000928	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—muscle cancer	1.68e-05	0.000923	CcSEcCtD
Pemetrexed—Body temperature increased—Methotrexate—muscle cancer	1.68e-05	0.000923	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—muscle cancer	1.68e-05	0.000922	CcSEcCtD
Pemetrexed—Dyspnoea—Doxorubicin—muscle cancer	1.65e-05	0.000902	CcSEcCtD
Pemetrexed—Dyspepsia—Doxorubicin—muscle cancer	1.62e-05	0.00089	CcSEcCtD
Pemetrexed—Decreased appetite—Doxorubicin—muscle cancer	1.6e-05	0.000879	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—muscle cancer	1.59e-05	0.000873	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—muscle cancer	1.59e-05	0.000872	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—muscle cancer	1.58e-05	0.000865	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—muscle cancer	1.58e-05	0.000865	CcSEcCtD
Pemetrexed—Hypersensitivity—Methotrexate—muscle cancer	1.57e-05	0.000861	CcSEcCtD
Pemetrexed—Asthenia—Methotrexate—muscle cancer	1.53e-05	0.000838	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Doxorubicin—muscle cancer	1.51e-05	0.000827	CcSEcCtD
Pemetrexed—Pruritus—Methotrexate—muscle cancer	1.51e-05	0.000826	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—muscle cancer	1.47e-05	0.000804	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—muscle cancer	1.46e-05	0.0008	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—muscle cancer	1.46e-05	0.0008	CcSEcCtD
Pemetrexed—Diarrhoea—Methotrexate—muscle cancer	1.46e-05	0.000799	CcSEcCtD
Pemetrexed—Dizziness—Methotrexate—muscle cancer	1.41e-05	0.000772	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—muscle cancer	1.36e-05	0.000745	CcSEcCtD
Pemetrexed—Vomiting—Methotrexate—muscle cancer	1.36e-05	0.000743	CcSEcCtD
Pemetrexed—Rash—Methotrexate—muscle cancer	1.34e-05	0.000737	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—muscle cancer	1.34e-05	0.000736	CcSEcCtD
Pemetrexed—Asthenia—Doxorubicin—muscle cancer	1.32e-05	0.000726	CcSEcCtD
Pemetrexed—Pruritus—Doxorubicin—muscle cancer	1.31e-05	0.000716	CcSEcCtD
Pemetrexed—Nausea—Methotrexate—muscle cancer	1.27e-05	0.000694	CcSEcCtD
Pemetrexed—Diarrhoea—Doxorubicin—muscle cancer	1.26e-05	0.000692	CcSEcCtD
Pemetrexed—Dizziness—Doxorubicin—muscle cancer	1.22e-05	0.000669	CcSEcCtD
Pemetrexed—Vomiting—Doxorubicin—muscle cancer	1.17e-05	0.000643	CcSEcCtD
Pemetrexed—Rash—Doxorubicin—muscle cancer	1.16e-05	0.000638	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—muscle cancer	1.16e-05	0.000637	CcSEcCtD
Pemetrexed—Nausea—Doxorubicin—muscle cancer	1.1e-05	0.000601	CcSEcCtD
